Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report
The prognosis of patients with advanced melanoma is poor. The five-year recurrence rate is approximately 70%, whereas the overall survival rate is only 4%–10%. We report the case of a 61-year-old male patient with metastatic melanoma (B-Raf+). The tumor load of the patient was significantly reduced...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co. Ltd.
2021-12-01
|
| Series: | Chinese Journal of Plastic and Reconstructive Surgery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2096691121001096 |
| _version_ | 1811198660857298944 |
|---|---|
| author | Yang Yang Nanhang Lu Jiaqi Liu Jianying Gu |
| author_facet | Yang Yang Nanhang Lu Jiaqi Liu Jianying Gu |
| author_sort | Yang Yang |
| collection | DOAJ |
| description | The prognosis of patients with advanced melanoma is poor. The five-year recurrence rate is approximately 70%, whereas the overall survival rate is only 4%–10%. We report the case of a 61-year-old male patient with metastatic melanoma (B-Raf+). The tumor load of the patient was significantly reduced after the application of dabrafenib plus trametinib (“D+T”) and radiotherapy. Further, it is suggested that medical staff should conduct a comprehensive analysis of the patient’s condition when dealing with adverse events (AEs) associated with such malignant tumors to provide evidence for adopting the appropriate targeted treatment or radiotherapy and nursing mode and achieve the best treatment effect. |
| first_indexed | 2024-04-12T01:33:49Z |
| format | Article |
| id | doaj.art-393ee194b51a476580e265cf752a7cbd |
| institution | Directory Open Access Journal |
| issn | 2096-6911 |
| language | English |
| last_indexed | 2024-04-12T01:33:49Z |
| publishDate | 2021-12-01 |
| publisher | KeAi Communications Co. Ltd. |
| record_format | Article |
| series | Chinese Journal of Plastic and Reconstructive Surgery |
| spelling | doaj.art-393ee194b51a476580e265cf752a7cbd2022-12-22T03:53:22ZengKeAi Communications Co. Ltd.Chinese Journal of Plastic and Reconstructive Surgery2096-69112021-12-0134193196Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case reportYang Yang0Nanhang Lu1Jiaqi Liu2Jianying Gu3Department of Plastic and Reconstructive Surgery, Zhongshan Hospital of Fudan University, Shanghai 200032, ChinaDepartment of Plastic and Reconstructive Surgery, Zhongshan Hospital of Fudan University, Shanghai 200032, ChinaCorresponding authors. Department of Plastic and Reconstructive Surgery, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Xuhui District, Shanghai 200032, China.; Department of Plastic and Reconstructive Surgery, Zhongshan Hospital of Fudan University, Shanghai 200032, ChinaCorresponding authors. Department of Plastic and Reconstructive Surgery, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Xuhui District, Shanghai 200032, China.; Department of Plastic and Reconstructive Surgery, Zhongshan Hospital of Fudan University, Shanghai 200032, ChinaThe prognosis of patients with advanced melanoma is poor. The five-year recurrence rate is approximately 70%, whereas the overall survival rate is only 4%–10%. We report the case of a 61-year-old male patient with metastatic melanoma (B-Raf+). The tumor load of the patient was significantly reduced after the application of dabrafenib plus trametinib (“D+T”) and radiotherapy. Further, it is suggested that medical staff should conduct a comprehensive analysis of the patient’s condition when dealing with adverse events (AEs) associated with such malignant tumors to provide evidence for adopting the appropriate targeted treatment or radiotherapy and nursing mode and achieve the best treatment effect.http://www.sciencedirect.com/science/article/pii/S2096691121001096MelanomaB-Raf gene mutationTargeted therapyDabrafenib plus trametinib |
| spellingShingle | Yang Yang Nanhang Lu Jiaqi Liu Jianying Gu Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report Chinese Journal of Plastic and Reconstructive Surgery Melanoma B-Raf gene mutation Targeted therapy Dabrafenib plus trametinib |
| title | Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report |
| title_full | Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report |
| title_fullStr | Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report |
| title_full_unstemmed | Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report |
| title_short | Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report |
| title_sort | fast reaction and long duration application of dabrafenib plus trametinib in treatment of metastatic melanoma with b raf v600e mutation a case report |
| topic | Melanoma B-Raf gene mutation Targeted therapy Dabrafenib plus trametinib |
| url | http://www.sciencedirect.com/science/article/pii/S2096691121001096 |
| work_keys_str_mv | AT yangyang fastreactionandlongdurationapplicationofdabrafenibplustrametinibintreatmentofmetastaticmelanomawithbrafv600emutationacasereport AT nanhanglu fastreactionandlongdurationapplicationofdabrafenibplustrametinibintreatmentofmetastaticmelanomawithbrafv600emutationacasereport AT jiaqiliu fastreactionandlongdurationapplicationofdabrafenibplustrametinibintreatmentofmetastaticmelanomawithbrafv600emutationacasereport AT jianyinggu fastreactionandlongdurationapplicationofdabrafenibplustrametinibintreatmentofmetastaticmelanomawithbrafv600emutationacasereport |